Last updated: September 2, 2026
Atazanavir sulfate and cobicistat are mature HIV medicines with sharply different commercial positions. Atazanavir, marketed principally as Reyataz and combined with cobicistat as Evotaz, faces broad generic erosion and declining clinical use. Cobicistat, marketed as Tybost and included in Gilead’s Stribild, Genvoya, and Evotaz, remains commercially relevant as a pharmacokinetic enhancer but is dependent on combination products and is increasingly displaced by unboosted integrase-inhibitor regimens.
The principal market risk is generic substitution for atazanavir. The principal strategic risk for cobicistat is therapeutic migration away from boosted protease inhibitors and cobicistat-containing fixed-dose combinations. Neither ingredient has a meaningful biosimilar risk because both are chemically synthesized small molecules.
What are atazanavir sulfate and cobicistat used for?
Atazanavir is an HIV-1 protease inhibitor. Cobicistat is a CYP3A inhibitor used to increase systemic exposure to certain antiretroviral drugs. Cobicistat has no meaningful independent antiviral activity at its intended pharmacologic use.
| Product |
Active ingredients |
Original sponsor or commercial owner |
FDA approval |
Primary role |
| Reyataz |
Atazanavir sulfate |
Bristol-Myers Squibb |
2003 |
HIV protease inhibitor |
| Tybost |
Cobicistat |
Gilead Sciences |
2014 |
Pharmacokinetic enhancer |
| Evotaz |
Atazanavir sulfate and cobicistat |
Bristol-Myers Squibb/Gilead collaboration |
2015 |
Boosted protease-inhibitor combination |
| Stribild |
Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate |
Gilead Sciences |
2012 |
Complete HIV regimen |
| Genvoya |
Elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide |
Gilead Sciences |
2015 |
Complete HIV regimen |
The FDA approved atazanavir for treatment of HIV-1 infection in combination with other antiretroviral agents. Cobicistat is approved to enhance exposure to atazanavir, darunavir, and elvitegravir in specified regimens, subject to important drug-interaction and renal-safety restrictions. (FDA, 2023a; FDA, 2023b)
How has the HIV market changed for atazanavir and cobicistat?
The HIV market has moved from boosted protease inhibitors toward integrase strand transfer inhibitor, or INSTI, regimens. Biktarvy, Triumeq, Dovato, and other INSTI-based products have gained share because of high efficacy, simplified dosing, lower interaction burden, and strong guideline positioning.
The U.S. Department of Health and Human Services guidelines identify bictegravir- and dolutegravir-based regimens as preferred initial therapies for most adults. Boosted atazanavir has a narrower role and is not a leading first-line option. (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024)
Principal market shifts
| Market driver |
Effect on atazanavir |
Effect on cobicistat |
| INSTI adoption |
Reduces use of protease inhibitors |
Reduces need for pharmacokinetic boosting |
| Generic entry |
Directly lowers price and branded volume |
Limited direct impact on standalone Tybost, but pressures Evotaz |
| Treatment simplification |
Favors single-tablet INSTI regimens |
Penalizes multi-component boosted regimens |
| Drug-interaction concerns |
Reduces attractiveness of atazanavir |
Directly limits cobicistat use |
| Renal and metabolic monitoring |
Creates switching pressure |
Adds restrictions to cobicistat-containing products |
| Long-acting HIV therapy |
May reduce oral regimen volume over time |
Makes chronic oral boosting less attractive |
Atazanavir retains value in patients who cannot tolerate or access INSTI regimens, in selected treatment-experienced populations, and in markets where cost determines regimen selection. Those segments are commercially smaller than the historical first-line market.
What is the financial trajectory for Reyataz and atazanavir?
Reyataz’s commercial trajectory has followed the standard mature-antiretroviral pattern: rapid expansion after launch, a plateau during the late 2000s and early 2010s, and sustained decline after competing regimens and generic products became available.
Bristol-Myers Squibb reported Reyataz revenue of approximately $1.5 billion in 2014, followed by declines in subsequent years. Reported revenue fell to approximately $1.2 billion in 2015 and approximately $1.0 billion in 2016, before further erosion from competition and reduced use. The company later stopped presenting Reyataz as a major growth product in its principal financial disclosures. (Bristol-Myers Squibb, 2015, 2017)
Reported product revenue should not be interpreted as current market size. Companies changed product portfolios, geographic rights, and disclosure categories over time. Evotaz revenue was not generally disclosed as a large standalone financial line, and Tybost revenue has been embedded within broader Gilead HIV reporting or remained immaterial relative to Gilead’s leading HIV products.
Financial trajectory by product
| Product or ingredient |
Historical position |
Current commercial direction |
| Reyataz |
Major branded protease inhibitor |
Declining, generic-exposed |
| Generic atazanavir |
Price-led substitution opportunity |
Low-margin, tender- and payer-driven |
| Tybost |
Niche enhancer product |
Stable to declining, dependent on combination use |
| Evotaz |
Specialized boosted combination |
Small and declining |
| Stribild |
Earlier-generation complete regimen |
Replaced by newer tenofovir alafenamide and INSTI products |
| Genvoya |
Important mid-generation HIV product |
Durable but pressured by Biktarvy and newer regimens |
Gilead’s HIV franchise remained large through 2023 and 2024, but its growth was concentrated in Biktarvy, Genvoya, Descovy, and newer or higher-value products rather than Tybost or Evotaz. Biktarvy became the central growth driver in the portfolio, while older boosted regimens faced continuing cannibalization. (Gilead Sciences, 2024)
When does atazanavir lose exclusivity?
Atazanavir’s principal U.S. composition-of-matter and product exclusivity period has expired. The drug was approved in 2003, and generic atazanavir products have been approved in the United States. Market exclusivity is therefore no longer the main barrier to competition.
The relevant distinction is between:
- FDA regulatory exclusivity, which has expired;
- Orange Book-listed patents, which may have provided later protection for particular formulations, combinations, or uses; and
- practical market access, which depends on generic supply, payer substitution, manufacturing economics, and product-specific approvals.
The Orange Book should be reviewed for the current listing status of Reyataz and Evotaz patents because listings can change through delisting, expiration, or product-specific updates. FDA Orange Book data identify listed patents and exclusivity, but they do not establish that every listed patent would withstand validity or infringement litigation. (FDA, 2024a)
Atazanavir patent exposure
| Protection category |
Commercial status |
| Atazanavir active ingredient |
Expired or no longer commercially blocking in the United States |
| Atazanavir sulfate dosage forms |
Generic competition exists; residual claims may be product-specific |
| Reyataz labeling |
Method-of-use protection is limited by generic-labeling and carve-out rules |
| Evotaz combination |
Combination-specific claims may remain relevant, but do not restore broad atazanavir exclusivity |
| Manufacturing processes |
Potentially relevant in litigation or supply negotiations, but generally less powerful than composition claims |
Atazanavir generic litigation has historically involved Abbreviated New Drug Application, or ANDA, filings and Paragraph IV certifications. The commercial result has been generic entry rather than preservation of a durable branded monopoly.
What is the Orange Book status of Reyataz, Evotaz, and Tybost?
The Orange Book is most relevant to approved drug products that contain the relevant active ingredients. Reyataz and Evotaz are listed drug products; Tybost is a separate cobicistat product.
An Orange Book listing does not mean that a patent covers every use of the active ingredient. Patent scope must be analyzed claim by claim, including:
- active pharmaceutical ingredient claims;
- salt and crystalline-form claims;
- capsule or tablet composition claims;
- fixed-dose combination claims;
- dosing and coadministration claims;
- treatment-method claims; and
- manufacturing-process claims.
For atazanavir, the economic importance of Orange Book patents has fallen because generic manufacturers can enter after expiration of blocking claims or use non-infringing labels. For cobicistat, commercially important protection has often been connected to combination regimens rather than Tybost as a standalone enhancer.
Which companies are challenging atazanavir patents?
Generic competition for atazanavir has involved multiple ANDA sponsors, including large multinational and specialty-generic companies. Teva and Dr. Reddy’s have been associated with generic atazanavir products in the U.S. market, although availability and active marketing can vary by year, strength, formulation, and supplier.
A Paragraph IV challenge can create a 30-month FDA approval stay when statutory conditions are met. A first-filer may also obtain 180-day generic exclusivity, but that exclusivity can be forfeited or altered under the Hatch-Waxman framework. The commercial impact depends on whether the generic is approved, whether litigation settles, and whether other ANDA applicants can enter.
For a mature product such as atazanavir, the presence of approved generics is more material than the historical identity of the first Paragraph IV filer. The market typically transitions from patent litigation to price competition and supply reliability.
What patents protect cobicistat and cobicistat-containing products?
Cobicistat protection is more complex than atazanavir protection because the commercial asset is distributed across several products and combinations.
Cobicistat patent layers
| Patent layer |
Products potentially affected |
Commercial relevance |
| Cobicistat compound and analog claims |
Tybost and combination products |
Core ingredient protection; expiration timing is jurisdiction-specific |
| Pharmaceutical composition claims |
Tybost, Evotaz, Stribild, Genvoya |
May delay product-specific generic entry |
| Combination claims |
Evotaz and complete regimens |
Can protect a defined combination without blocking all individual ingredients |
| Method-of-use claims |
Boosting atazanavir, darunavir, or elvitegravir |
Narrower protection; generic labeling strategies matter |
| Formulation and manufacturing claims |
Tablets, stability, process controls |
Potential litigation leverage but usually narrower than composition claims |
Gilead’s cobicistat-containing products benefited from a portfolio of patents and regulatory exclusivities. The estate is strongest where several components, formulations, and combination claims overlap. It is weaker where a generic manufacturer can market individual components separately or use a permitted label carve-out.
Cobicistat also appears in products with different sponsors or commercial arrangements. That fragmentation increases the need for product-by-product analysis rather than ingredient-only analysis.
How strong is the patent estate for atazanavir sulfate versus cobicistat?
Cobicistat has the stronger remaining strategic patent position, but its value is tied to declining boosted-regimen demand. Atazanavir has greater generic exposure and a weaker ability to support premium pricing.
| Factor |
Atazanavir sulfate |
Cobicistat |
| Composition protection |
Mature and largely expired in the U.S. |
More recent product and combination protection |
| Generic competition |
Established |
More limited at the complete-product level |
| Clinical demand |
Declining |
Declining as a booster, with continuing use in legacy regimens |
| Differentiation |
Low |
Moderate, based on regimen compatibility |
| Pricing power |
Low |
Higher in protected combinations, limited for standalone use |
| Litigation value |
Mostly residual |
Greater for combination and formulation disputes |
| Long-term outlook |
Commodity-like generic market |
Niche component of aging branded regimens |
Patent strength is not equivalent to commercial value. A technically strong patent around a combination has limited economic value if physicians and guidelines are moving to another drug class.
What generic entry risks exist for Reyataz and Evotaz?
Reyataz
Reyataz faces the highest generic-entry risk. Generic atazanavir can compete directly on the active ingredient, particularly in public-payer, Medicaid, hospital, and international tender channels. The main constraints are manufacturing economics, demand concentration, and the willingness of suppliers to maintain a low-volume product.
Likely commercial outcomes include:
- continued branded-to-generic substitution;
- price compression;
- reduced pharmacy benefit manager reimbursement;
- lower inventory levels;
- possible supplier exits; and
- continued use in price-sensitive markets.
Evotaz
Evotaz faces a more complicated risk profile. A generic applicant may need to address the atazanavir-cobicistat combination, formulation claims, and any listed patents. Even if a complete generic combination is delayed, clinicians may use separate generic or alternative components when clinically appropriate.
Evotaz’s market is smaller than Reyataz’s historical market. That reduces the expected return from litigation and can delay the entry of multiple suppliers. It also means that one successful generic or authorized-generic strategy could materially reduce branded volume.
Does cobicistat face biosimilar risk?
No. Cobicistat is a small-molecule chemical drug, not a biologic. Its competitive pathway is the ANDA generic pathway, not the biosimilar pathway under the Public Health Service Act.
The relevant risks are:
- generic cobicistat tablets;
- generic or authorized-generic combination products;
- substitution from cobicistat-boosted regimens to unboosted INSTI regimens; and
- lower demand for complete regimens containing cobicistat.
The regulatory risk is therefore primarily abbreviated-application and labeling risk rather than biosimilar interchangeability.
What regulatory status does the FDA assign to these products?
Atazanavir sulfate, cobicistat, Reyataz, Tybost, and Evotaz are FDA-approved HIV products. They carry warnings involving drug interactions, hepatic effects, renal monitoring, and regimen-specific contraindications.
Cobicistat inhibits CYP3A and can increase exposure to coadministered drugs. This is pharmacologically useful but clinically burdensome. The interaction profile is a structural disadvantage against newer regimens that require less boosting.
Atazanavir also has regimen-specific limitations, including risks involving hyperbilirubinemia, cardiac conduction, acid-reducing agents, and food or absorption requirements. These factors restrict its use in certain patient populations and increase switching pressure. (FDA, 2023a; FDA, 2023b)
What licensing deals affect atazanavir and cobicistat?
The commercial history includes collaboration between Bristol-Myers Squibb and Gilead around HIV products and combinations. Bristol-Myers Squibb developed and commercialized Reyataz, while Gilead developed cobicistat and incorporated it into Stribild, Genvoya, and other regimens. Evotaz combined the two companies’ assets.
Gilead’s acquisition of Pharmasset did not create cobicistat, but Gilead retained control of the commercial HIV platform in which cobicistat became strategically important. The economic value of cobicistat has therefore been captured mainly through combination products, not through standalone Tybost sales.
No licensing arrangement can offset the broader class shift toward INSTI-based treatment. Collaboration improved product positioning but did not eliminate lifecycle decline.
What patent litigation and settlement issues affect the market?
Atazanavir’s major litigation risk has historically been ANDA-based patent litigation under the Hatch-Waxman Act. The most important commercial questions are whether a generic applicant:
- files a Paragraph IV certification;
- triggers a 30-month stay;
- obtains a favorable court judgment;
- settles for a defined entry date;
- receives 180-day exclusivity; or
- enters at risk before final resolution.
For cobicistat combinations, litigation risk is more likely to focus on product-specific patents, fixed-dose combinations, formulation claims, and methods of using cobicistat as a booster. Settlement terms may establish an agreed generic-entry date without creating an immediate public record of the economic terms.
No broad conclusion about a current settlement date should be drawn from historical litigation alone. Product-specific Orange Book and court records govern the operative position.
How does atazanavir compare with competing HIV drugs?
| Drug or regimen |
Class |
Commercial position |
Competitive effect |
| Atazanavir/cobicistat |
Protease inhibitor plus booster |
Mature and declining |
Loses share to INSTIs |
| Darunavir/cobicistat |
Protease inhibitor plus booster |
More durable in treatment-experienced use |
Competes directly with atazanavir |
| Biktarvy |
INSTI-based single-tablet regimen |
Major growth product |
Primary source of switching |
| Triumeq |
Dolutegravir-based regimen |
Mature but important |
Reduces need for boosted therapy |
| Dovato |
Two-drug INSTI regimen |
Growing simplified option |
Reduces pill burden |
| Genvoya |
Elvitegravir/cobicistat regimen |
Established but aging |
Maintains cobicistat demand while facing Biktarvy |
| Long-acting cabotegravir/rilpivirine |
Injectable regimen |
Expanding niche |
Reduces dependence on daily oral therapy |
Atazanavir is disadvantaged by its interaction profile, tolerability considerations, and lower guideline priority. Cobicistat retains utility where boosting is required, but that requirement is itself declining.
What are the geographic market dynamics?
The United States has the clearest generic erosion because of formal ANDA pathways, Orange Book patent litigation, and pharmacy substitution. European markets are more fragmented. Patent expiry, national reimbursement rules, tendering, reference pricing, and parallel trade can produce materially different launch timing and price erosion.
Lower- and middle-income markets may preserve demand for atazanavir because of procurement economics and treatment-program formularies. However, international sales are typically more price-sensitive and less attractive to branded suppliers. Cobicistat availability may be constrained by the need to supply a complete regimen and maintain regulatory approvals across multiple countries.
What manufacturing and intellectual-property barriers remain?
Atazanavir manufacturing is commercially feasible for experienced generic suppliers, but low-volume products can face active-ingredient sourcing and quality-control constraints. The main barriers are scale, regulatory compliance, and reliable supply rather than fundamental chemistry.
Cobicistat requires tighter control of formulation, stability, impurity profiles, and drug-drug interaction labeling. Combination tablets create additional manufacturing complexity because each active ingredient must meet release, uniformity, and stability requirements.
Manufacturing patents may provide incremental protection, but process claims rarely reproduce the economic strength of a valid composition patent. A supplier with approved manufacturing capacity and established HIV distribution can therefore compete effectively after core patent barriers fall.
What generic launch scenarios are most likely?
Scenario 1: Continued atazanavir price erosion
This is the base case. Generic atazanavir remains available, branded Reyataz loses volume, and payer substitution increases. Pricing approaches a low-margin mature-generic structure.
Scenario 2: Limited generic supply
If demand becomes too small, some suppliers may exit. Prices may stabilize temporarily, but branded growth is unlikely to return. Supply concentration would increase procurement risk.
Scenario 3: Evotaz-specific generic entry
A complete generic atazanavir/cobicistat product would accelerate Evotaz erosion. Even without a direct combination substitute, separate-component substitution could reduce branded demand.
Scenario 4: Regimen migration without direct generic substitution
Patients move from atazanavir or cobicistat-containing products to Biktarvy, dolutegravir-based regimens, or injectable therapy. This scenario produces the greatest long-term volume loss because it removes demand rather than merely transferring it to a generic supplier.
Key Takeaways
- Atazanavir sulfate is a mature, generic-exposed HIV protease inhibitor with declining branded revenue.
- Reyataz lost its historical strategic position as HIV treatment shifted toward INSTI-based regimens.
- Cobicistat remains commercially useful but is dependent on combination products and the shrinking boosted-regimen segment.
- Evotaz has a smaller market and more complicated product-specific patent exposure than Reyataz.
- Neither ingredient faces biosimilar competition; the relevant pathway is generic ANDA competition.
- The strongest remaining IP value lies in cobicistat-containing combinations, formulations, and specific methods of use.
- The largest commercial threat is therapeutic substitution into Biktarvy, dolutegravir-based regimens, and long-acting therapy.
- Geographic and payer dynamics will determine the speed of generic erosion, but the long-term direction is downward for atazanavir and legacy cobicistat products.
FAQs
Is atazanavir sulfate still a preferred first-line HIV treatment?
No. Current U.S. guidelines generally prioritize INSTI-based regimens. Atazanavir may remain appropriate for selected treatment-experienced or clinically constrained patients.
Is Tybost the same as ritonavir?
No. Both are pharmacokinetic enhancers, but cobicistat and ritonavir have different pharmacologic profiles, regulatory labels, interaction patterns, and commercial histories.
Can generic atazanavir be substituted for Reyataz?
An FDA-approved generic may be therapeutically substitutable under applicable state pharmacy laws and product-specific requirements. Substitution depends on the approved strength, dosage form, and formulary rules.
Does Evotaz have stronger exclusivity than Reyataz?
Evotaz may have combination-specific and formulation-specific protections that do not apply to Reyataz. Those protections do not recreate broad exclusivity for atazanavir as an active ingredient.
What is the principal investment risk for cobicistat?
The main risk is demand contraction from the declining use of boosted regimens. Patent expiry is important, but therapeutic displacement is the larger long-term commercial issue.
References
Bristol-Myers Squibb. (2015). 2014 annual report. Bristol-Myers Squibb Company.
Bristol-Myers Squibb. (2017). 2016 annual report. Bristol-Myers Squibb Company.
Gilead Sciences, Inc. (2024). 2023 annual report. Gilead Sciences, Inc.
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
U.S. Food and Drug Administration. (2023a). Reyataz (atazanavir sulfate) prescribing information. FDA.
U.S. Food and Drug Administration. (2023b). Tybost (cobicistat) and Evotaz prescribing information. FDA.
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
